CVR 36184779Private limited company (ApS)Engroshandel med medicinalvarer og sygeplejeartikler (464610)BallerupFounded 17 Sep 2014
Dandex has recorded no changes to this company since it began following the register.
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about Viatris ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexEmployees
35
CVR registry, Aug 2026
-1 (-2.8%) over 12 months
Revenue
329.1M
DKK, annual report 2025
-26.5% on 2024
Result
+13.7M
DKK, annual report 2025
Equity
170.6M
DKK, annual report 2025
Meda AB100% of capital and votes, since 14 Jul 2021
Lars Henrik Andreas Rejnussince 27 Feb 2026
Bente Brumoensince 12 Sep 2024
100% of capital and votessince 14 Jul 2021
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
100% of capital and votes11 Feb 2015 to 14 Jul 2021
CVR records founders at incorporation. It does not record whether they are alive or still involved.
24 Apr 2023 to 6 Nov 2026.
17 Sep 2014 to 6 Nov 2026.
Aug 2026, monthly: 35 employees, 31 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 3 | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 1 | 2 | 3 | 4 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 7 | 8 | 9 | 13 | 14 | 14 | 14 | 14 | 14 | 16 | 17 | 17 | 20 | 20 | 20 | 21 | 23 | 23 | 24 | 25 | 25 | 29 | 30 | 29 | 30 | 32 | 29 | 31 | 33 | 31 | 31 | 34 | 32 | 32 | 35 | 32 | 47 | 45 | 43 | 45 | 52 | 43 | 46 | 43 | 42 | 44 | 43 | 41 | 42 | 43 | 42 | 43 | 44 | 41 | 43 | 43 | 43 | 44 | 45 | 43 | 45 | 43 | 42 | 42 | 44 | 40 | 41 | 42 | 39 | 39 | 40 | 40 | 41 | 40 | 41 | 41 | 41 | 41 | 41 | 41 | 42 | 42 | 42 | 42 | 42 | 42 | 41 | 42 | 43 | 35 | 35 | 36 | 36 | 36 | 35 | 35 | 35 | 35 | 34 | 34 | 35 | 34 | 36 | 36 | 36 | 35 |
| FTE | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 6 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 7 | 8 | 11 | 12 | 12 | 12 | 13 | 13 | 14 | 15 | 15 | 18 | 18 | 18 | 19 | 21 | 21 | 21 | 22 | 23 | 26 | 26 | 25 | 27 | 29 | 27 | 28 | 29 | 29 | 30 | 29 | 27 | 28 | 30 | 28 | 42 | 42 | 40 | 40 | 45 | 41 | 39 | 37 | 38 | 39 | 38 | 38 | 37 | 40 | 38 | 40 | 40 | 40 | 40 | 40 | 41 | 41 | 41 | 41 | 41 | 40 | 38 | 39 | 40 | 38 | 38 | 39 | 36 | 34 | 36 | 37 | 39 | 36 | 38 | 36 | 38 | 37 | 38 | 38 | 38 | 37 | 37 | 37 | 39 | 39 | 37 | 39 | 36 | 31 | 32 | 33 | 32 | 33 | 32 | 31 | 32 | 31 | 31 | 31 | 31 | 29 | 32 | 32 | 32 | 31 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Monthly Feb 2015 to Aug 2026.
CVR changed its monthly method in Oct 2019, so a step at that month need not be real.
Latest Aug 2026, published 21 Oct 2026. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Not reported | 439,662 | 467,398 | 447,761 | 329,092 |
| Gross profit | 60,734 | Not reported | Not reported | Not reported | Not reported |
| Operating profit | +24,076 | +17,279 | +28,722 | +23,805 | +17,438 |
| Result for the year | +18,079 | +11,107 | +19,603 | +17,943 | +13,735 |
| Equity | 108,188 | 119,295 | 138,898 | 156,841 | 170,576 |
| Total assets | 286,805 | 358,839 | 240,438 | 277,738 | 200,255 |
| Employees (average) | 38 | 41 | 35 | 37 | 33 |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | Not reported | 10.4% | 6.3% | -4.2% | -26.5% |
| EBIT margin (overskudsgrad) | Not reported | 3.9% | 6.2% | 5.3% | 5.3% |
| EBITDA | 29,001 | 21,849 | 33,293 | 28,376 | 21,938 |
| EBITDA margin | Not reported | 5% | 7.1% | 6.3% | 6.7% |
| Employee growth (vækst i antal ansatte) | 22.6% | 7.9% | -14.6% | 5.7% | -10.8% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -29,543note 1 | -3,053note 1 | -1,378note 1 | 0note 1 | Not reportednote 2 |
| Gearing, NIBD / EBITDA | Net cashnote 1 | Net cashnote 1 | Net cashnote 1 | Net cashnote 1 | Not reportednote 2 |
| ROIC (afkast af investeret kapital) | 41.2%note 1 | 13.7%note 1 | 17.7%note 1 | 12.5%note 1 | Not reportednote 2 |
| Capex (investeringer i anlægsaktiver) | 0note 3 | 0note 3 | 0note 3 | 0note 3 | 0note 3 |
| Capex % of sales (investeringer i procent af omsætningen) | Not reported | 0%note 3 | 0%note 3 | 0%note 3 | 0%note 3 |
| NIBD incl. group and owner balances (NIBD inkl. koncern- og ejermellemværender) | 85,891note 1 | 126,633note 1 | 57,823note 1 | 70,960note 1 | Not reportednote 2 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. No cash flow statement: included in the group's (ÅRL § 86, stk. 4).
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 27 Jun 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 4 Jul 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 5 Jul 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 30 Jun 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 29 Jun 2022
Each registered value from the day it took effect, newest first.
Merger (Fusion), as the continuing company (Fortsættende selskab)
From CVR, read 6 Nov 2026. Text such as the signing rule and purpose is shown as registered.
27 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Direktion:
Fratrådte:
Jan Ulrik Stevnsborg, den 27.02.2026.
Tiltrådte:
Lars Henrik Andreas Rejnus, (adm. dir), den 27.02.2026.
Bestyrelse:
Fratrådte:
Jan Ulrik Stevnsborg, (formand), den 27.02.2026.
Tiltrådte:
Lars Henrik Andreas Rejnus, (formand), den 27.02.2026.
Bestyrelse:
Fratrådte:
Kurt Glud, den 24.04.2023, Luis Rodolfo Birbuet, den 24.04.2023.
Tiltrådte:
Arun Narayan, den 24.04.2023, Bente Brumoen, den 24.04.2023.
Vedtægter ændret: 01.09.2021
Nyt navn: Viatris ApS
Nyt binavn: Mylan Denmark ApS
Slettet binavn: Viatris ApS
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er fusioneret med CVR-nummer: 46032217 MEDA A/S, der samtidigt er opløst.
Vedtægter ændret: 31.08.2021
Nye binavne: Meda ApS, Cross Pharma ApS, Medanica ApS, Medic Team ApS, Recip ApS, Scanmeda ApS
Kapitalforhøjelsen er besluttet den 31.08.2021.
kr. 1.000,00, indbetalt ved fusion, kurs 6.458.261,00.
Kapitalen udgør herefter kr. 101.000,00.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 36184779 Mylan Denmark ApS (fortsættende), der tillige driver virksomhed under navnene Viatris ApS og CVR-nummer: 46032217 MEDA A/S (ophørende), der tillige driver virksomhed under navnene SCANMEDA A/S, MEDIC TEAM A/S, RECIP A/S, MEDANICA A/S, CROSS PHARMA A/S.
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 36184779 Mylan Denmark ApS og CVR-nummer: 46032217 MEDA A/S må antages at være tilstrækkeligt sikrede efter fusionen.
Vedtægter ændret: 07.07.2021
Nyt binavn: Viatris ApS
Vedtægter ændret: 25.06.2021
Selskabet tegnes af en direktør, af et medlem af bestyrelsen eller af den samlede bestyrelse.
Bestyrelse:
Fratrådte:
Jose Javier Cotarelo, den 19.02.2021.
Tiltrådte:
Luis Rodolfo Birbuet, den 19.02.2021.
Vedtægter ændret: 01.07.2019
Nyt navn: Mylan Denmark ApS
Ny adresse: Borupvang 1, 2750 Ballerup
Ny kommune: Ballerup
Bestyrelse:
Fratrådte:
Anthonius Matthijs van 't Hullenaar, den 20.11.2018.
Tiltrådte:
Jose Javier Cotarelo, den 20.11.2018.
Bestyrelse:
Fratrådte:
Gitte Jürgens, den 18.07.2018.
Tiltrådte:
Kurt Glud, den 18.07.2018.
Direktion:
Fratrådte:
Vidar Sie, den 18.07.2018.
Bestyrelse:
Fratrådte:
Anthonius Matthijs van 't Hullenaar, den 05.09.2017.
Tiltrådte:
Anthonius Matthijs van 't Hullenaar, den 05.09.2017.
Bestyrelse:
Fratrådte:
Jean-Yves Brault, den 05.09.2017.
Tiltrådte:
Anthonius Matthijs van 't Hullenaar, den 05.09.2017.
Bestyrelse:
Fratrådte:
Jean-Yves Brault (formand), den 07.10.2016, Sandeep Puri, den 07.10.2016.
Tiltrådte:
Jan Ulrik Stevnsborg (formand), den 07.11.2016, Olof Frykman, den 07.10.2016.
Direktion:
Tiltrådte:
Jan Ulrik Stevnsborg, den 07.10.2016.
Bestyrelse:
Fratrådte:
Jacek Glinka, den 28.01.2016.
Tiltrådte:
Jean-Yves Brault (formand), den 28.01.2016.
Revision:
Fratrådte:
ERNST & YOUNG Godkendt Revisionspartnerselskab, den 02.09.2015.
Tiltrådte:
CVR-NR. 33963556 DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, Weidekampsgade 6, 2300 København S, den 02.09.2015.
CVR-nummer:
36184779.
NAVN:
BGP PRODUCTS ApS.
Adresse: c/o Regus Fairway House, Arne Jacobsens Allé 7, 5., 2300 København S.
Kommune: København.
Bestyrelse:
Udtrådt af bestyrelsen:
Thomas Craig Freyman, den 27.02.2015, Björn Fredrik Anders Björnulfson, den 27.02.2015.
Indtrådt i bestyrelsen:
Jacek Glinka, den 27.02.2015, Sandeep Puri, den 27.02.2015.
Vedtægter ændret:
09.02.2015.
Kapitalforhøjelse:
kr. 50.000,00 indbetalt i værdier, kurs 28.200,00.
Kapitalen udgør herefter kr. 100.000,00.
Ny adresse:
c/o Abbott Laboratories A/S, Emdrupvej 28C, 2100 København Ø.
Stiftelsesdato:
17.09.2014.
Seneste vedtægtsdato:
17.09.2014.
Kapital:
kr. 50.000,00.
Indbetalingsmåde:
Indbetalt kontant kr. 50.000,00 til kurs 100,00.
Stifter:
CVR-NR. 31528615 ABBOTT LABORATORIES A/S, Emdrupvej 28, c., 2100 København Ø, den 17.09.2014.
Bestyrelse:
Thomas Craig Freyman (formand), den 17.09.2014, Björn Fredrik Anders Björnulfson, den 17.09.2014, Salg-og Marketing direktør Palle Michael Christensen, den 17.09.2014.
Direktion:
Salg-og Marketing direktør Palle Michael Christensen, den 17.09.2014.
Selskabet tegnes af en direktør og et medlem af bestyrelsen i fællesskab eller af den samlede bestyrelse.
Revision:
CVR-NR. 30700228 ERNST & YOUNG P/S, Osvald Helmuths Vej 4, postboks 250, 2000 Frederiksberg, den 17.09.2014.
Første regnskabsår:
17.09.2014 - 31.12.2015.
Regnskabsår:
01.01 - 31.12.
2 registered in CVR.
P-number 1022063495Solvang 8, 3450 Allerød
P-number 1019703947Borupvang 1, 2750 Ballerup
No other current company drawn.
No other current company drawn.
No other current company drawn.